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Case Report
AbstractHuman T-cell Lymphotropic virus type 1 (HTLV-1) is the etiological agent of AdultT-cell Leukemia/Lymphoma (ATLL) and HTLV-1 Associated Myelopathy/TropicalSpastic Paraparesis (HTM/TSP). Areas of extremely high HTLV-1 prevalence aresurrounded by areas of middle or very low prevalence. ATLL is an aggressivelymphoproliferative malignancy of peripheral T cells, with an incidence of less than5% in HTLV-1-infected individuals. ATLL developed in the majority of cases inindividuals who were infected with HTLV-1 by their mothers due to prolongedbreastfeeding. In non-endemic areas, ATLL is usually limited to immigrants, theirsexual partners and descendants from endemic regions. Very few cases of ATLLhave been diagnosed in recipient patients few years after an organ transplantationor blood transfusion worldwide. Achieving an accurate and fast diagnosisof ATLL can be challenging due to the lack of professional experience, delayedconsultation and difficulty in its sub-classification. We present a case of a delayedonset of a chronic ATLL in an 18-years-old male who was transfused with bloodcomponents as a premature newborn in Buenos Aires, a non-endemic city of SouthAmerica.
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1. IntroductionHuman T-Cell Leukemia Virus Type 1 (HTLV-1) is theetiological agent of Adult T-Cell Lymphoma/Leukemia(ATLL) and HTLV-1-Associated Myelopathy/TropicalSpastic Paraparesis (HAM/TSP). HTLV-1 can be acquiredby mother-to-child transmission through prolongedbreastfeeding or sexual and parenteral transmission.Approximately 5-10 million individuals are infected withHTLV-1 worldwide and, among them, 1%–5% willdevelop an associated pathology. HTLV-1 infection tendsto be focally endemic in well-defined geographic regions.In non-endemic areas, HTLV-1 infection is reportedamong immigrants, their sexual partners anddescendants from endemic areas and among at-riskpopulations.1 ATLL is a highly aggressive neoplasm ofpleomorphic activated T lymphocytes, which develops inthe majority of cases in adulthood after a long latency
since, in virtually all cases, individuals are infected bytheir mother due to prolonged breastfeeding.2Worldwide very few cases of ATLL have been diagnosedin recipient patients 2 to 3 years after bloodtransfusion or organ transplantation .3, 4 Recently, a caseof ATLL has been demonstrated after sexualtransmission.5 The diagnosis criteria for ATLL includesthe detection of antibodies against HTLV-1 in theperipheral blood of a patient with T-Cell Lymphoma orLeukemia and the presence of typical lymphocytes(“flower cells”) circulating in peripheral blood ofpatients with leukemic manifestations. In case of tumors,a monoclonal insertion of HTLV-1 proviral DNA into thetumor cells is also observed. Immuno phenotypicdiagnosis is also required,  tumor cells are of T cellorigin and exhibit a mature activated memory
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CD4+CD25+ phenotype.6 ATLL is an heterogeneousdisease clinically divided into four subtypes (acute,lymphoma, chronic and smoldering) according toleukemic manifestations in the blood, organinvolvement, serum lactate dehydrogenase (LDH) levelsand corrected serum calcium levels; skin lesion may bepresent.7 The most common form of presentation isacute, characterized by the presence of organomegalyand leukemic cells in the blood. Hypercalcaemia with orwithout lytic bone lesions is present in half of thesepatients. The chronic form is characterized bylymphocytosis, which may be stable for months or evenyears, skin manifestations, no organomegaly except forlymph nodes, absence of hypercalcemia and usuallynormal LDH levels. The chronic type progress is muchslower, less aggressive, and is divided into two subtypes:the unfavorable chronic type and the favorable chronictype with no poor prognostic factors (normal values forserum lactate dehydrogenase (LDH), serum blood ureanitrogen and serum albumin).8Patients with smolderingATLL are usually asymptomatic or manifest skin rashesand there is no lymphocytosis. Lymphoma presents withno evidence of blood involvement but involvement oforgans, lymph nodes, hypercalcemia and high LDH level.The rate of survival varies depending on the subtyperanging from 4 to 6 months for the acute type to 34months to more than 5 years for the smoldering type.Antiviral therapy is currently the standard treatment inEurope and USA for patients with ATLL (except for thelymphoma type).9 We report the case of a youngArgentine male, whose mother was HTLV-1 negative,who developed a chronic ATLL at the age of 18 afterreceiving a blood transfusion in the first months of life inthe non-endemic capital city of Argentina.
2. Case presentationAn 18-year-old Argentine male attended for the firsttime a dermatology service of a Public Hospital in April2015 due to a periorbital edema and cutaneous nodularlesions in the right side of the face, which were soft inconsistency and not adhered to deep plans. The patientcomplained of painless hassle sensation in the right eyefor 6 months prior to consultation and until aestheticaldiscomfort (Figure 1A).The patient underwent a thorough evaluation to excludenodular fasciitis and other differential diagnosis. Humanimmunodeficiency virus serology was negative andthere was no evidence of an underlyingimmunocompromised status. No other sign or symptomwere identified; however, peripheral blood examinationrevealed leukocytosis and 70% of neutrophils among20.000 white blood cells (WBCs) in blood smear. Arheumatic disease was suspected, but three months later(in July), a lymphocytosis (14,000 lymphocytes/ mm3)was observed and the patient was derived to thehaematology unit. A new examination determinedabnormal T lymphocytes with a characteristic
phenotype: CD3+, CD4+, TCRαβ+, TCRγδ-, CD25+, CD10-,CD8-, CD28+, CD5+, CD2+, (78%), CD7-/HLA-DR-,HLA-DR+D by flow cytometry supporting a T celllymphoproliferative disorder suggestive ofNon-Hodgking´s Lymphoma (NHL). Two months later,an eyelid cutaneous biopsy showed T lymphocytesinfiltration with immunophenotype compatible withperipheral T-Cell Lymphoma and a bone marrow biopsyconfirmed the diagnosis (Figure 2).
Figure 1: Photograph of the patient showing right (A) andleft (B) periorbital edema and cutaneous nodule.
Figure 2: Histopathology of skin nodule (left forearm)showing the subepithelial tissue infiltrated by a populationof uniform, predominantly small-sized T lymphocytes withfolded nuclei.
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Figure 3: Blood peripheral smear showing typicalabnormal medium size T-lymphocytes, with agranular andweakly basophilic cytoplasm and convoluted nucleus,named “flower cells” characteristic of ATLL (May-GrünwaldGiemsa staining, 100X).Diagnosis for HTLV-1/2 infection was performed. Ascreening immunoassay (Particle-agglutination assay,Serodia HTLV-1, Fujirebio Inc, Tokyo, Japan) wasreactive and the result was confirmed by Western Blot(MP Diagnostics HTLV BLOT 2.4, Singapore), giving atypical complete sero-reactivity (p19, p24, p53, GD21,and MTA-1) to HTLV-1 infection. Proviral load wasdetermined in peripheral blood mononuclear cells(PBMCs) (9,8 copies/100 cells) by quantitative real timePCR (q-PCR) and 5% typical “flower” cells wereobserved in the blood smears (Figure 3).The patient reported not to have ever had sexualcontacts, so mother to child transmission was suspected.The mother has undergone HTLV-1/2 diagnosis and wasconfirmed serologically and molecularly as negative forHTLV-1/2 infection. A deeply clinical survey wasperformed to the patient and his mother twice, withdifferent physicians and separately in order to reveal thetransmission route. He was born and raised in BuenosAires city, had no sexual partners, however the motherreported two blood transfusions received by the patientduring his first month of life as he was premature andsuffered of a serious hyaline illness. After 40 days (inSeptember), the size of the nodule had grown andsimilar ones appeared at the right forearm and at theother side of the face (Figure 1 B).No systemic symptoms were present andcomputed-tomography scans showed no lymph nodes,organomegaly or lytic bone lesions. Absence ofhypercalcaemia and laboratory parameters with no poorprognostic factors finally classified ATLL as a favorablechronic type with skin manifestations according to theShimoyama classification.7,8A combination of zidovudine(600 mg/day)/ pegylated IFN-alpha (90ucg/kg/week)was initiated. At the last follow-up visit (in June),lymphocytosis decreased as well as both facial nodules
diminished without other abnormalities. Other factors(calcium and LDH) had normal values. The patient’swritten consent was obtained for this report.
3. DiscussionThis reported case is remarkable for two reasons: firstly,the development of a favorable chronic ATLL afterHTLV-1 transmission by blood transfusion, is very rarelyreported. Secondly, our patient had an asymptomaticcourse of HTLV-1 infection and developed the disease at18 years old exhibiting cutaneous manifestations, inopposition to the commonly early onset ofpostransfutional ATLL. This delayed onset aftertransfusion, but earlier in comparison to infectionthrough breastfeeding might be due to reduce immuneresponse at the time of infection in this prematurenewborn.In this case, the patient’s mother was negative forHTLV-1 infection and the only risk factor found was thetwo blood transfusions received as a newborn in 1997.Although, the detection of anti-HTLV-1/2 antibodies hadbeen recommended in Argentina in that year by theImmunohemathology and Hemotherapy ArgentineAssociation (AAHI), it only became mandatory 8 yearslater, in 2005. This case highlights the challenge inreaching an accurate and timely diagnosis of ATLL andits sub-classification in areas were the virus is notendemic. A close coordination between physicians,dermatologists and hematologists is vital in patientswith this disease, as a misdiagnosis can have importantimpact in their life expectancy. Particularly, in thesechronic forms of the disease it is interesting to notifythat treatment with chemotherapy is not efficient andoften is worse than the watch and wait policy Incontrast, the combination of AZT and Interferon mayinduce a high rate of response, which may last long.10
4. ConclusionThis case describes the occurrence of favorable chronicATLL with cutaneous manifestation as first symptom inan Argentine young male patient. This data confirms thehypothesis that ATLL can develop following bloodtransfusion, apart from breastfeeding, with a delayedonset after infection at least in premature newborns.The possibility of developing ATLL due to seropositiveblood transfusion should be kept in mind consideringthe date of mandatory screening for HTLV-1 in bloodbanks and the implementation of this surveillance ineach country.
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